Antibacterial activity of synthetic fire ant venom: The solenopsins and isosolenopsins

American Journal of the Medical Sciences

Volumn 338, Issue 4, 2009, Pages 287-291

  Sullivan, Donna C ^a   Flowers, Heather ^a   Rockhold, Robin ^a   Herath, H M T Bandara ^b   Nanayakkara, N P Dhammika ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Antibacterial; Fire ant venom; Isosolenopsin; Solenopsin; Synthetic alkaloids

Indexed keywords

ALKALOID; ANT VENOM; INSECT VENOM; ISOSOLENOPSIN; SOLENOPSIN A; UNCLASSIFIED DRUG;

ANT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; FIRE ANT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SOLENOPSIS INVICTA;

EID: 70350158191     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181af8270     Document Type: Article

References (23)

1. Aronstam RS, Edwards MW, Daly JW, et al. Interactions of piperidine derivatives with the nicotinic cholinergic receptor complex from torpedo electric organ. Neurochem Res 1988;13:171-176
2. Hoffman D, Dove D, Jacobson R. Allergens in Hymenoptera venom. J Allergy Clin Immunol 1988;82:818-827
3. Hoffman D. Fire ant venom allergy. Allergy 1995;50:535-544
4. Howell G, Butler J, deShazo R, et al. Cardiodepressant and neurologic actions of Solenopsis invicta (imported fire ant) venom alkaloids. Ann Allergy Asthma Immunol 2005;94:380-386
5. Blum M, Walker R, Callahan P, et al. Chemical, insecticidal, and antibiotic properties of fire ant venom. Science 1958;128:306-307
6. Jouvenaz D, Blum M, MacConnell J. Antibacterial activity of venom alkaloids from the imported fire ant, Solenopsis invicta Buren. Antimicrob Agents Chemother 1972;2:291-293
7. Storey GK, Vander Meer RK, Boucias DG, et al. Effect of fire ant (Solenopsis invicta) venom alkaloids on the in vitro germination and development of selected entomogenous fungi. J Invertebr Pathol 1991; 58:88-95.
8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard M7-A6, 6th ed. Wayne, PA: NCCLS; 2003.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: fifteenth Informational Supplement M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
10. Gillis L, White H, Whitehurst A, et al. Vancomycin-tolerance among clinical isolates of Streptococcus pneumoniae in Mississippi during 1999-2001. Am J Med Sci 2005;330:65-68
11. Craig W. Pharmacokinetic/Pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
12. Boswell F, Andrews J, Wise R. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimicrob Agents Chemother 1997;41:1377-1379
13. Boswell F, Andrews J, Wise R. Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 1997;39:415-418
14. Buren W. Revisionary studies on the taxonomy of the imported fire ants. J Ga Entomol Soc 1972;7:1-26.
15. Park J, Kaufmann GF, Bowen JP, et al. Solenopsin A, a venom alkaloid from the fire ant Solenopsis invicta, inhibits quorum-sensing signaling in Pseudomonas aeruginosa. J Infect Dis 2008;198:1198-1201
16. Flowers H, Sullivan D, Wiggers T, et al. Antibiotic surveillance of Streptococcus pneumoniae in Mississippi. Clin Lab Sci 2006;19:5-11.
17. Garrison MW, Anderson DE, Campbell DM, et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996;40:2859-2864
18. Gilligan PH, Lum G, Vandamme P, et al. Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea and Acidovorax. In: Murray PR, editor. Manual of clinical microbiology, 8th ed. Washington: American Society of Microbiology; 2003: pp. 729-748
19. Swenson J, Hindler J, Jorgensen J. Special phenotypic methods for detecting antimicrobial resistance. In: Murray PR, editor. Manual of clinical microbiology, 8th ed. Washington: American Society of Microbiology; 2003: p. 1178-1195
20. Mueller M, de la Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 2004;48:369-377
21. Wise R, Andrews J, Boswell F, et al. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998; 42:721-728
22. May J, Chan C, King A, et al. Time-kill studies of tea tree oils on clinical isolates. J Antimicrob Chemother 2000;45:639-643
23. Boost M, Ko W, O'Donoghue M. Penicillin and vancomycin tolerance among clinical isolates of Streptococcus pneumoniae in Hong Kong. Hong Kong Med J 2003;9:415-418